What is the main reason for the expected charge in Regeneron's Q3 2025 results?

The main reason for the expected charge is an acquired in-process research and development (IPR&D) expense of approximately $83 million. This is primarily related to an upfront payment of $80 million made under a license agreement with Hansoh Pharmaceuticals Group Company Limited.

How will this charge affect Regeneron's earnings per share (EPS) for Q3 2025?

Regeneron expects this IPR&D charge to reduce its net income per diluted share, on both a GAAP and non-GAAP basis, by approximately $0.68 for the third quarter of 2025.

Are these financial results final?

No, the financial results for the third quarter of 2025 are preliminary and have not been finalized. They are subject to the company's financial statement closing procedures, and actual results may differ.

What is an IPR&D charge and why isn't it typically forecasted?

An acquired IPR&D charge relates to in-process research and development acquired in various transactions, such as licensing agreements. Regeneron does not forecast these charges because their future occurrence, magnitude, and timing are uncertain.

REGN 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed October 6, 2025. Cited figures are marked; the original filing is the authoritative source.

Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report disclosing an expected acquired in-process research and development (IPR&D) charge of approximately $83 million^a on a pre-tax basis for the third quarter of 2025.

This charge is primarily linked to an $80 million^b upfront payment made to Hansoh Pharmaceuticals Group Company Limited under a 2025 license agreement. The company anticipates this IPR&D charge will reduce both GAAP and non-GAAP net income per diluted share by approximately $0.68 for the quarter.

02—Key points

Key Highlights

Expected $83 million pre-tax IPR&D charge for Q3 2025.
Charge primarily driven by an $80 million upfront payment related to a license agreement with Hansoh Pharmaceuticals Group Company Limited.
Anticipated negative impact of approximately $0.68 per diluted share on both GAAP and non-GAAP net income for Q3 2025.
IPR&D charges are not typically forecasted due to their inherent uncertainty.
Financial results for Q3 2025 are preliminary and subject to closing procedures.
The information provided is not considered "filed" for purposes of Section 18 of the Securities Exchange Act.
Includes standard forward-looking statements and a note on non-GAAP financial measures.

03—Questions

Frequently Asked Questions

What is the main reason for the expected charge in Regeneron's Q3 2025 results?
The main reason for the expected charge is an acquired in-process research and development (IPR&D) expense of approximately $83 million. This is primarily related to an upfront payment of $80 million made under a license agreement with Hansoh Pharmaceuticals Group Company Limited.
How will this charge affect Regeneron's earnings per share (EPS) for Q3 2025?
Regeneron expects this IPR&D charge to reduce its net income per diluted share, on both a GAAP and non-GAAP basis, by approximately $0.68 for the third quarter of 2025.
Are these financial results final?
No, the financial results for the third quarter of 2025 are preliminary and have not been finalized. They are subject to the company's financial statement closing procedures, and actual results may differ.
What is an IPR&D charge and why isn't it typically forecasted?
An acquired IPR&D charge relates to in-process research and development acquired in various transactions, such as licensing agreements. Regeneron does not forecast these charges because their future occurrence, magnitude, and timing are uncertain.

04—Continue

← View all 8-K filings